{"generic":"Interferon Alfa-2b","drugs":["Interferon Alfa-2b","Intron A"],"mono":[{"id":"6gqws0","title":"Generic Names","mono":"Interferon Alfa-2b"},{"id":"6gqws1","title":"Dosing and Indications","sub":[{"id":"6gqws1b4","title":"Adult Dosing","mono":"<ul><li>dosage forms and strengths are indication-specific and are not interchangeable<\/li><li><b>AIDS-related Kaposi's sarcoma:<\/b> 30 million international units\/m(2) IM\/SUBQ 3 times\/wk until disease progression or maximal response is achieved after 16 weeks<\/li><li><b>Carcinoid tumor:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Condyloma acuminatum, Involving external surfaces of the genital and perianal areas:<\/b> 1 million international units (0.1 mL per lesion) INTRALESIONALLY 3 times\/wk on alternate days for 3 weeks; maximum 5 lesions per course; may repeat a second course at 12 to 16 weeks<\/li><li><b>Follicular lymphoma, Initial treatment in conjunction with anthracycline-containing combination chemotherapy:<\/b> 5 million international units SUBQ 3 times\/wk for up to 18 months<\/li><li><b>Hairy cell leukemia:<\/b> 2 million international units\/m(2) IM\/SUBQ 3 times\/wk for up to 6 months<\/li><li><b>Hepatitis C, chronic, In patients with compensated liver disease:<\/b> 3 million international units IM\/SUBQ 3 times\/ wk for 16 weeks; for patients responding to therapy, treatment should be extended to 18 to 24 months<\/li><li><b>Malignant melanoma, Adjuvant to surgical therapy for high-risk patients:<\/b> induction, 20 million international units\/m(2) IV 5 consecutive days\/week for 4 weeks; maintenance, 10 million international units\/m(2) SUBQ 3 times\/week for 48 weeks<\/li><li><b>Multiple myeloma:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Type B viral hepatitis, chronic, With compensated liver disease:<\/b> 5 million international units IM\/SUBQ daily OR 10 million international units IM\/SUBQ 3 times\/wk for 16 weeks, or for 48 weeks for hepatitis B e antigen-negative patients<\/li><\/ul>"},{"id":"6gqws1b5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness in pediatric patients less than 18 years of age not established except for chronic hepatitis B and chronic hepatitis C; safety and effectiveness not established in children less than 1 year and 3 years of age, respectively<\/li><li>dosage forms and strengths are indication-specific and are not interchangeable<\/li><li><b>Type B viral hepatitis, chronic, With compensated liver disease:<\/b> (1 to 17 years) 3 million international units\/m(2) SUBQ 3 times\/wk for the first week, then 6 million international units\/m(2) SUBQ 3 times\/wk; total duration of therapy 16 to 24 weeks; MAX 10 million international units 3 times\/wk<\/li><\/ul>"},{"id":"6gqws1b6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic:<\/b> (follicular lymphoma) permanently discontinue therapy if SGOT exceeds 5 times the upper limit of normal<\/li><li><b>hematologic:<\/b> (follicular lymphoma) delay chemotherapy if neutrophil count less than 1500\/mm(3) or platelet count less than 75,000\/mm(3)<\/li><li><b>hematologic:<\/b> (follicular lymphoma) withhold therapy for neutrophil count less 1000\/mm(3) or platelet count less than 50,000 mm(3); reduce dose by 50% for neutrophil count greater than 1000\/mm(3) but less than 1500\/mm(3); increase to starting dose with neutrophil count greater than 1500\/mm(3)<\/li><li><b>renal:<\/b> (follicular lymphoma) permanently discontinue therapy if serum creatinine greater than 2 mg\/dL<\/li><li><b>hepatic:<\/b> (malignant melanoma) withhold therapy if SGPT\/SGOT greater than 5 to 10 times upper limit of normal; once resolved, restart therapy at 50% of previous dose; permanently discontinue if SGPT\/SGOT greater than 10 times upper limit of normal<\/li><li><b>hematologic:<\/b> (malignant melanoma) withhold therapy if granulocyte count greater than 250\/mm(3) but less than 500\/mm(3); once resolved, restart therapy at 50% of previous dose; permanently discontinue if granulocyte count less than 250\/mm(3)<\/li><li><b>hematologic:<\/b> (chronic hepatitis B) WBC count less than 1.5 x 10(9)\/L; granulocyte count less than 0.75 x 10(9)\/L; platelet count less than 50 x 10(9) \/L) reduce dose 50%<\/li><li><b>hematologic:<\/b> (chronic hepatitis B) WBC count less than 1 x 10(9)\/L; granulocyte count less than 0.5 x 10(9)\/L; platelet count less than 25 x 10(9)\/L) permanently discontinue treatment<\/li><li><b>severe adverse reactions:<\/b> (hairy cell leukemia, AIDS-related Kaposi's sarcoma, chronic hepatitis B, and chronic hepatitis C patients) reduce dose by 50% or temporarily discontinue therapy if severe adverse reactions develop; once adverse reactions resolve, resume treatment at 50% of normal dose; discontinue permanently if severe reactions persist or recur<\/li><li><b>severe adverse reactions:<\/b> (malignant melanoma) temporarily discontinue therapy if severe adverse reactions develop; once adverse reactions resolve, resume treatment at 50% of normal dose; discontinue permanently if severe reactions persist or recur<\/li><\/ul>"},{"id":"6gqws1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>AIDS-related Kaposi's sarcoma<\/li><li>Condyloma acuminatum, Involving external surfaces of the genital and perianal areas<\/li><li>Follicular lymphoma, Initial treatment in conjunction with anthracycline-containing combination chemotherapy<\/li><li>Hairy cell leukemia<\/li><li>Hepatitis C, chronic, In patients with compensated liver disease<\/li><li>Malignant melanoma, Adjuvant to surgical therapy for high-risk patients<\/li><li>Type B viral hepatitis, chronic, With compensated liver disease<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Carcinoid tumor<\/li><li>Chronic myeloid leukemia<\/li><li>Follicular lymphoma, In conjunction with non-anthracycline chemotherapy<\/li><li>Hepatitis C, acute<\/li><li>Laryngeal papillomatosis<\/li><li>Multiple myeloma<\/li><li>Ovarian cancer<\/li><li>Polycythemia vera<\/li><li>Renal cell carcinoma<\/li><li>Skin cancer<\/li><li>Thrombocytosis<\/li><\/ul>"}]},{"id":"6gqws2","title":"Black Box Warning","mono":"<b>Injection (Solution; Powder for Solution)<\/b><br\/>May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely with periodic clinical and laboratory evaluations. Discontinue therapy with persistently severe or worsening signs or symptoms of these conditions.<br\/>"},{"id":"6gqws3","title":"Contraindications\/Warnings","sub":[{"id":"6gqws3b9","title":"Contraindications","mono":"<ul><li>autoimmune hepatitis<\/li><li>hemoglobinopathies (eg, thalassemia major, sickle cell anemia) (in combination with ribavirin)<\/li><li>liver disease, decompensated<\/li><li>hypersensitivity to interferon alfa or to any component of the product<\/li><li>hypersensitivity to ribavirin or to any component of the product (in combination with ribavirin)<\/li><li>men with female partners who are pregnant (in combination with ribavirin)<\/li><li>pregnancy; may cause birth defects and death of the exposed fetus; use at least 2 forms of contraception and perform monthly tests; do not start ribavirin without a negative pregnancy test (in combination with ribavirin)<\/li><li>renal function impairment (CrCl less than 50 mL\/min) (in combination with ribavirin)<\/li><\/ul>"},{"id":"6gqws3b10","title":"Precautions","mono":"<ul><li>autoimmune disorders (eg, thrombocytopenia, vasculitis, Raynaud's phenomenon, rheumatoid arthritis, lupus erythematosus, rhabdomyolysis, psoriasis), including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; discontinuation may be necessary<\/li><li>infections, including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, discontinue use<\/li><li>ischemic conditions, including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, discontinue use<\/li><li>neuropsychiatric events (eg suicide, suicidal and homicidal ideation, depression, aggressive behavior), including fatal or life-threatening events, may be induced or aggravated; monitoring recommended; if symptoms are persistently severe or worsen, discontinue use<\/li><li>AIDS-related Kaposi's sarcoma with rapidly progressive visceral disease; use not recommended<\/li><li>bone marrow toxicity, resulting in severe cytopenias (including aplastic anemia), has occurred; monitoring recommended; discontinuation may be necessary<\/li><li>cardiovascular disease, including history of myocardial infarction or arrhythmic disorder; increased risk for cardiovascular adverse events; monitoring recommended<\/li><li>cardiovascular events (eg, hypotension, arrhythmias, tachycardia, cardiomyopathy, myocardial infarction) have occurred<\/li><li>cerebrovascular disease; ischemic and hemorrhagic events have been reported<\/li><li>chronic hepatitis B and C patients; risk for liver disease exacerbation, including jaundice, hepatic encephalopathy, hepatic failure, and death; discontinue therapy if signs\/symptoms of liver failure occur<\/li><li>cirrhosis; increased risk of hepatic decompensation and death; monitoring recommended; discontinuation may be required<\/li><li>coagulation disorders (eg, thrombophlebitis, pulmonary embolism); increased risk of fever and flu-like symptoms<\/li><li>debilitating medical conditions (eg, history of pulmonary disease (COPD), diabetes mellitus prone to ketoacidosis); increased risk of fever and flu-like symptoms<\/li><li>dental and periodontal disorders have been reported; monitoring recommended (in combination with ribavirin)<\/li><li>diabetes mellitus may be induced or aggravated; if uncontrolled disease preexists, do not initiate therapy; if uncontrolled disease develops during therapy, discontinue treatment<\/li><li>encephalopathy has been reported, particularly in elderly patients and higher doses<\/li><li>hepatotoxicity, including fatalities, has been reported; monitoring recommended; discontinuation may be required<\/li><li>human plasma derivative (albumin in powder for injection); infectious agent risk, including viruses and theoretical risk of Creutzfeldt-Jacob disease<\/li><li>hypersensitivity reactions, serious and acute (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis), have been reported; discontinuation of therapy recommended<\/li><li>immunosuppressed transplant recipients; not recommended due to risk for liver disease exacerbation, including jaundice, hepatic encephalopathy, hepatic failure, and death<\/li><li>myelosuppression, severe; increased risk of fever and flu-like symptoms<\/li><li>obtundation and coma have been reported, particularly in elderly patients and higher doses; discontinuation may be required<\/li><li>ophthalmologic disorders (eg, vision loss, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, serous retinal detachment) may be induced or aggravated; monitoring recommended; discontinue therapy if new or worsening disorders develop<\/li><li>pancreatitis may occur due to elevated triglyceride levels; may require discontinuation of therapy<\/li><li>pediatric patients, primarily adolescents; increased risk of suicidal ideation or attempts during treatment and after discontinuation<\/li><li>psychiatric and substance use disorders, co-occurring or history; may exacerbate psychiatric disorder; monitoring recommended; discontinuation may be required<\/li><li>pulmonary function impairment (eg, dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, sarcoidosis), including fatal or life-threatening events, may be induced or aggravated; discontinuation may be necessary<\/li><li>renal impairment and\/or those over the age of 50 years; monitoring recommended; risk of anemia (in combination with ribavirin)<\/li><li>thyroid abnormalities (hypothyroidism or hyperthyroidism) may be induced or aggravated; if uncontrolled disease preexists, do not initiate therapy; if uncontrolled disease develops during therapy, discontinue treatment<\/li><\/ul>"},{"id":"6gqws3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"6gqws3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"6gqws4","title":"Drug Interactions","sub":{"2":{"id":"6gqws4b15","title":"Moderate","mono":"<ul>Ribavirin (probable)<\/ul>"}}},{"id":"6gqws5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Alopecia (adults, up to 38%; pediatrics, 17% to 50%)<\/li><li><b>Endocrine metabolic:<\/b>Weight decreased (adults, up to 3%; pediatric chronic hepatitis B, 3%; pediatric chronic hepatitis C, 20% to 50%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (adults, up to 21%; pediatrics, 20% to 50%), Diarrhea (malignant melanoma, 35%; follicular lymphoma, 19%; hairy cell leukemia, 18%; condylomata acuminata, 2%; Kaposi sarcoma, 18% to 45%; chronic hepatitis C adults, 13%; chronic hepatitis B adults, 8% to 19%; chronic hepatitis B pediatrics, 12%; chronic hepatitis C pediatrics, 20% to 50%), Loss of appetite (malignant melanoma, 69%; follicular lymphoma, 21%; hairy cell leukemia, 19%; condylomata acuminata, 1%; Kaposi sarcoma, 38% to 41%; chronic hepatitis C adults, 14%; chronic hepatitis B, 43% to 53%; chronic hepatitis C pediatrics, greater than 50%), Nausea and vomiting (malignant melanoma, 66%; chronic hepatitis B pediatric, 40%)<\/li><li><b>Hematologic:<\/b>Neutropenia, All grades (malignant melanoma, 92%; chronic hepatitis C, 9%; chronic hepatitis B pediatrics, 14%; chronic hepatitis C pediatrics, 34%)<\/li><li><b>Hepatic:<\/b>AST\/SGOT level raised (malignant melanoma, 63%,; follicular lymphoma, 24%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (adults, up to 21%; pediatrics, 10% to 50%), Myalgia (malignant melanoma, 75%; follicular lymphoma, 16%; hairy cell leukemia, 39%; condylomata acuminata, 44%; Kaposi sarcoma, 28% to 34%; chronic hepatitis C adults, 43%; chronic hepatitis B adults, 40% to 59%; chronic hepatitis B pediatrics, 27%; chronic hepatitis C pediatrics, 20% to 50%)<\/li><li><b>Neurologic:<\/b>Asthenia (chronic hepatitis B, 5% to 15%; hairy cell leukemia, 7%; Kaposi sarcoma, up to 11%; chronic hepatitis C, 40%; follicular lymphoma, 63%), Headache (adults, 21% to 62%; pediatrics, greater than 50%)<\/li><li><b>Psychiatric:<\/b>Depression (Adults, 3% to 40%; pediatrics, 3% to 13%)<\/li><li><b>Other:<\/b>Fatigue (malignant melanoma, 96%; hairy cell leukemia, 61%; Kaposi sarcoma, 48% to 84%; chronic hepatitis B adults, 69% to 75%; chronic hepatitis C adults, 23%; condylomata acuminata, 18%; follicular lymphoma, 8%; chronic hepatitis B pediatrics, 71%; chronic hepatitis C pediatrics, greater than 50%), Fever (adults, 34% to 86%; pediatrics, greater than 50%), Influenza-like symptoms (malignant melanoma, 10%; follicular lymphoma, 18%; hairy cell leukemia, 37%; Kaposi sarcoma, 45% to 79%; chronic hepatitis C adults, 26%; chronic hepatitis B adults, up to 5%; chronic hepatitis B pediatrics, up to 100%; chronic hepatitis C pediatrics, 20% to 50%), Shivering (malignant melanoma, 54%; hairy cell leukemia, 46%; condylomata acuminata, 45%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia (less than 5%), Cardiomyopathy (Kaposi sarcoma, 2%; all indications, less than 5%), Hypotension (less than 5%), Myocardial infarction, Raynaud's disease (less than 5%), Supraventricular arrhythmia, Tachycardia (less than 5%), Vasculitis<\/li><li><b>Endocrine metabolic:<\/b>Decreased body growth, Diabetes mellitus (less than 5%), Hypertriglyceridemia (less than 5%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (less than 5%), Pancreatitis<\/li><li><b>Hematologic:<\/b>Anemia (adults all indications, less than 5%; malignant melanoma, 22%; pediatrics hepatitis C, 27%), Aplastic anemia, Thrombocytopenia (chronic hepatitis C, 10%; chronic hepatitis B pediatrics, 3%)<\/li><li><b>Hepatic:<\/b>Hepatic encephalopathy, Hepatotoxicity, Liver failure<\/li><li><b>Immunologic:<\/b>Autoimmune disease, Hypersensitivity reaction, Lupus erythematosus<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Coma (less than 5%), Decreased level of consciousness, Encephalopathy<\/li><li><b>Ophthalmic:<\/b>Functional visual loss, Optic disc edema, Optic neuritis, Retinal hemorrhage, Retinopathy, Thrombosis of retinal artery, Thrombosis of retinal vein<\/li><li><b>Psychiatric:<\/b>Suicidal (Less than 5%)<\/li><li><b>Respiratory:<\/b>Obliterative bronchiolitis, Pneumonia (less than 5%), Pneumonitis (less than 5%), Pneumothorax (less than 5%), Pulmonary embolism (less than 5%), Pulmonary hypertension, Pulmonary infiltrate, Sarcoidosis<\/li><\/ul>"},{"id":"6gqws6","title":"Drug Name Info","sub":{"0":{"id":"6gqws6b17","title":"US Trade Names","mono":"Intron A<br\/>"},"2":{"id":"6gqws6b19","title":"Class","mono":"<ul><li>Immunological Agent<\/li><li>Interferon, Alfa (class)<\/li><\/ul>"},"3":{"id":"6gqws6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"6gqws6b21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"6gqws7","title":"Mechanism Of Action","mono":"Interferon alfa-2b are proteins secreted in response to viral infection through binding at specific membrane receptors on the cell surface. Binding results in induction of certain enzymes, suppression of cell proliferation, enhancement of the phagocytic activity of macrophages, augmentation of specific cytotoxicity of lymphocytes for target cells, and inhibition of virus replication in virus-infected cells.<br\/>"},{"id":"6gqws8","title":"Pharmacokinetics","sub":{"0":{"id":"6gqws8b23","title":"Absorption","mono":"IM and Subcutaneous: time to peak concentration, 3 h to 12 h <br\/>"},"3":{"id":"6gqws8b26","title":"Excretion","mono":"<ul><li>Renal<\/li><li>Dialyzable: no (hemodialysis), no (peritoneal dialysis)<\/li><\/ul>"},"4":{"id":"6gqws8b27","title":"Elimination Half Life","mono":"<ul><li>IM and Subcutaneous: approximately 2 h to 3 h<\/li><li>IV: approximately 2 h<\/li><\/ul>"}}},{"id":"6gqws9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>administer in the evening if possible to enhance tolerability<\/li><li>acetaminophen may be administered at the time of injection to reduce the incidence of certain adverse reactions<\/li><li>(powder for injection) reconstitute with 1 mL sterile water for injection for immediate use or up to 24 hours if refrigerated at 2 to 8 degrees C (36 to 46 degrees F); withdraw appropriate dose for IM, SUBQ, intralesional, or IV infusion; IV infusion requires further dilution in 100 mL NS; discard any unused portion as formulation is preservative-free<\/li><li>(solution for injection) do not dilute; withdraw appropriate dose for IM, SUBQ, or intralesional; not recommended for IV use<\/li><li>(AIDS-related Kaposi sarcoma) use 50 million international units powder for injection; do not use the 18 million and 25 million international unit multidose vials of solution for injection due to inappropriate concentrations<\/li><li>(condylomata acuminata) use the 10 million international units powder for injection or multidose 25 million international units solution for injection; do not use the 18 million or 50 million international units powder for injection, or the 18 million international units multidose solution for injection for this indication<\/li><li>(malignant melanoma, induction phase) administer IV only; use powder for injection; do not use solution for injection in vials<\/li><\/ul><\/li><li><b>Intralesional<\/b><br\/>administer using a Tuberculin or similar syringe and a 25- to 30-gauge needle<br\/><\/li><li><b>Intravenous<\/b><br\/>(powder for injection) after reconstitution, dilute the appropriate dose in 100 mL NS for a minimum final concentration of 10 million international units\/100 mL and infuse over 20 minutes<br\/><\/li><\/ul>"},{"id":"6gqws10","title":"Monitoring","mono":"<ul><li>Chronic hepatitis B: hepatitis B e antigen, hepatitis B surface antigen, and serum ALT at end of therapy and 3 and 6 months post-therapy to assess efficacy<\/li><li>Chronic hepatitis C: serum ALT; baseline and at 3-month intervals to assess efficacy<\/li><li>Hairy cell leukemia: improvement in blood counts may indicate efficacy<\/li><li>Malignant melanoma, follicular lymphoma, AIDS-related Kaposi's sarcoma: objective evidence of tumor response may be indicative of efficacy<\/li><li>Condyloma acuminata: decreased size and\/or disappearance of lesions may be indicative of efficacy<\/li><li>Drug screening; consider periodically in patients with a history of psychiatric conditions or substance abuse<\/li><li>Electrolyte panel; baseline and periodically<\/li><li>CBC with differential, hemoglobin, and platelets; baseline and periodically<\/li><li>TSH; baseline and periodically<\/li><li>Hepatic function (including serum bilirubin, ALT, AST, alkaline phosphatase, and LDH); at baseline, weeks 2, 8, and 12 following therapy initiation, and then every 6 months while on therapy.<\/li><li>Chronic hepatitis B: CBC with platelets; baseline and at weeks 1, 2, 4, 8, 12, and 16 of therapy<\/li><li>Chronic hepatitis B: hepatic function with serum ALT, albumin, and bilirubin; baseline and at weeks 1, 2, 4, 8, 12, and 16 of therapy; if ALT flare, hepatic function including ALT, prothrombin time, alkaline phosphatase, and albumin at 2-week intervals<\/li><li>Chronic hepatitis C: CBC platelet; baseline, at weeks 1 and 2, and monthly thereafter<\/li><li>Chronic hepatitis C: TSH; baseline and 3 and 6 months after initiation of therapy<\/li><li>Chronic hepatitis C: pregnancy test, in patients receiving concomitant ribavirin; immediately prior to therapy and monthly during treatment<\/li><li>Malignant melanoma: differential WBC and hepatic function; weekly during induction, then monthly<\/li><li>Chest X-ray; baseline, then periodically if clinically indicated<\/li><li>ECG; baseline and during therapy in patients with preexisting cardiac abnormalities or advanced-stage cancer<\/li><li>Ophthalmologic exam; baseline in all patients, and during therapy in patients with preexisting ophthalmologic disorders<\/li><li>Psychiatric symptoms; in patients with a history of psychiatric conditions or substance abuse<\/li><li>Chronic hepatitis C: dental examination, regularly, in patients on interferon and ribavirin concomitantly<\/li><\/ul>"},{"id":"6gqws11","title":"How Supplied","mono":"<b>Intron A<\/b><br\/><ul><li>Injection Powder for Solution: 10 Million IU, 18 Million IU, 50 Million IU<\/li><li>Injection Solution: 6 Million IU\/ML, 10 Million IU\/ML<\/li><\/ul>"},{"id":"6gqws12","title":"Toxicology","sub":[{"id":"6gqws12b31","title":"Clinical Effects","mono":"<b>INTERFERONS<\/b><br\/>OVERDOSE: Data are limited. Shivers, myalgias, low grade fever and tachycardia have been reported. ADVERSE EFFECTS: \"flu-like\" symptoms (fever, chills, tachycardia, headache, malaise, and myalgias), hypotension, seizures, headache, lethargy, fatigue, elevated liver enzymes, leukopenia, & renal insufficiency; dysrhythmias in patients with underlying heart disease. Vomiting, diarrhea, hyperkalemia, hypocalcemia occur at high doses.<br\/>"},{"id":"6gqws12b32","title":"Treatment","mono":"<b>INTERFERONS<\/b><br\/><ul><li>Decontamination: Not indicated; broken down in the gut on oral ingestion.<\/li><li>Influenza-like illness: Treat with acetaminophen or non-steroidal anti-inflammatory agents<\/li><li>Hypotensive episode: Transient, usually requires no treatment;  0.9% NaCl 10-20 ml\/kg, dopamine, epinephrine if persistent<\/li><li>Monitoring of patient: CBC, hepatic &amp; renal function; ECG, calcium, potassium if severe overdose.<\/li><\/ul>"},{"id":"6gqws12b33","title":"Range of Toxicity","mono":"<b>INTERFERONS<\/b><br\/>Single doses greater than 100-200 million units associated with toxicity. <br\/>"}]},{"id":"6gqws13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.<\/li><li>This drug may cause loss of appetite, nausea, vomiting, depression, or influenza-like illness (fever, chills, headache, fatigue, myalgia).<\/li><li>Instruct patient to report any visual disturbances or signs\/symptoms of hepatotoxicity, renal dysfunction, neutropenia, thrombocytopenia, pancreatitis, or pneumonia.<\/li><li>Patient should report depression, suicidal ideation, or unusual changes in behavior.<\/li><li>Patients with a history of neuropsychiatric, autoimmune, ischemic, and infectious disorders should report any exacerbation of disease symptoms of these disorders during drug therapy.<\/li><li>If self-administered, teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><li>Patient should maintain adequate hydration during therapy.<\/li><li>Advise patient that concurrent narcotics, hypnotics, or sedatives should only be used under the supervision of healthcare professional.<\/li><li>Advise patient to call healthcare professional if a dose is missed, as drug should be given on a regular schedule.<\/li><\/ul>"}]}